new_0222_0175|CERE|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|price_next_month|price_second_month
new_0222_0175|CERE|1|Cerevel Therapeutics Holdings Inc Total Current Assets (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Cash and Short Term Investments (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Inventories (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Net PP&E (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Goodwill and Intangibles (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Total Liabilities (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Total Current Liabilities (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Total Long Term Liabilities (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Total Deposits (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Book Value (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Retained Earnings (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Treasury Stock (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc EV to Revenues|Cerevel Therapeutics Holdings Inc EV to Earnings|Cerevel Therapeutics Holdings Inc EV to Free Cash Flow|Cerevel Therapeutics Holdings Inc EV to Assets (Quarterly)|Cerevel Therapeutics Holdings Inc PS Ratio|Cerevel Therapeutics Holdings Inc PE Ratio|Cerevel Therapeutics Holdings Inc Price to Book Value|Cerevel Therapeutics Holdings Inc PEG Ratio|Cerevel Therapeutics Holdings Inc Debt to Equity Ratio|Cerevel Therapeutics Holdings Inc Dividend Yield|Cerevel Therapeutics Holdings Inc Shareholder Yield (TTM)|Cerevel Therapeutics Holdings Inc Percent of Shares Outstanding Short|Cerevel Therapeutics Holdings Inc Total Receivables (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Total Payables (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Total Capital Stock (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Return on Invested Capital|Cerevel Therapeutics Holdings Inc Quality Ratio Score|Cerevel Therapeutics Holdings Inc Momentum Score|Cerevel Therapeutics Holdings Inc Beta (1Y)|Cerevel Therapeutics Holdings Inc Sustainable Growth Rate (TTM)|Cerevel Therapeutics Holdings Inc Institutional Investor Ownership Percentage|Cerevel Therapeutics Holdings Inc Average Diluted Shares Outstanding (Quarterly)|Cerevel Therapeutics Holdings Inc Total Employees (Annual)|Cerevel Therapeutics Holdings Inc EPS Diluted (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Shares Outstanding|Cerevel Therapeutics Holdings Inc Repurchase of Capital Stock (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Ordinary Shares Number (Quarterly)|Cerevel Therapeutics Holdings Inc Payout Ratio|Cerevel Therapeutics Holdings Inc Quick Ratio (Quarterly)|Cerevel Therapeutics Holdings Inc Normalized Diluted EPS (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Stock Buybacks (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Effective Tax Rate (TTM)|Cerevel Therapeutics Holdings Inc Return on Equity|Cerevel Therapeutics Holdings Inc Net Income (TTM) (USD)|Cerevel Therapeutics Holdings Inc Revenue (TTM) (USD)|Cerevel Therapeutics Holdings Inc Dividend Per Share (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Revenue (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Gross Profit (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc SG&A Expense (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Pre-Tax Income (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Net Income (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Net Interest Income (Quarterly) (USD)|Cerevel Therapeutics Holdings Inc Price (USD)|Cerevel Therapeutics Holdings Inc Total Return Price (USD)|Cerevel Therapeutics Holdings Inc Enterprise Value (USD)|Cerevel Therapeutics Holdings Inc 30-Day Average Daily Volume|Cerevel Therapeutics Holdings Inc 1 Year Price Returns (Daily)||
new_0222_0175|CERE|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric||
new_0222_0175|CERE|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily||
new_0222_0175|CERE|5|91.4|91.4||91.25||91.4|91.4|91.4||91.4|91.4||||1.44918032787||||1.44985673352|||1.44985673352||15.1875|91.25|91.4|91.4|||30|30||29.5|91.4285714286|182.5|91.4285714286|36.7692307692||91.4|||91.4285714286|91.4|91.25||91.25|||||91.4285714286|91.4285714286|91.4285714286|91.4285714286|1.44985673352|1.44985673352|1.44985673352|1.45|1.45360824742||
new_0222_0175|CERE|6|5|5||4||5|5|5||5|5||||305||||349|||349||32|4|5|5|||3|4||2|7|2|7|13||5|||7|5|4||4|||||7|7|7|7|349|349|349|320|97||
new_0222_0175|CERE|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily||
new_0222_0175|CERE|202003||||||||||||||||||||||||||||||||||127.124||-0.4186||||||-0.4186|||||||||10.743|-53.208|-53.208|0.204|||||||
new_0222_0175|CERE|202006||||||||||||||||||||||||||||||||||127.124||-0.2102||||||-0.2102|||||||||12.973|-26.733|-26.717|0.005|||||||
new_0222_0175|CERE|202009|0.9492|0.6094||||7.9295|2.697|5.2325||142.5903|-3.1242||||||||9.1828|||||0.0289||0.1518|137.5908|||||||127.124||-0.3071|127.124||127.124|||-0.3071|||||||||10.336|-39.045|-39.04|0.001|10.3|10.3|1308.7678|||14.12|
new_0222_0175|CERE|202012|390.56|383.623||48.624||60.753|29.548|31.205||384.52|-390.91||||-12.6128||||5.4814|||||1.9234||4.993|0.013||||||83.0718|127.124|104|-0.27|127.124||127.124|||-0.27||0.0158||-152.142|||||11.761|-33.18|-33.177|0.014|16.58|16.58|1724.0929|588418.7667||12.87|15.16
new_0222_0175|CERE|202103|349.811|343.287||51.784||68.068|34.151|33.917||340.036|-441.891||||-9.6382||||5.1411|||||2.9158||7.755|0.013|||||||127.2255||-0.4|127.3251||127.3251|||-0.4||0.016||-149.915|||||14.01|-50.981|-50.981|0.015|13.73|13.73|1404.8866|251775.7||14.55|13.12
new_0222_0175|CERE|202106|331.782|327.06||51.92||97.117|29.257|67.86||293.887|-495.13||||-17.6249||||11.1224|||||3.6144||4.986|0.013|||||||127.4821||-0.42|127.5847||127.5847|||-0.42||0.0045||-176.437|||||13.216|-53.239|-53.239|0.01|25.62|25.62|2941.66|3512834.6||24.64|31.66
new_0222_0175|CERE|202109|675.029|669.676||51.98||104.4|30.8|73.6||629.08|-557.189||||-19.8975||||6.8998|||||3.0585||5.445|0.015|||10|3.2479|||144.0221|168|-0.43|147.136||147.136|||-0.43|-328.251|0.0015||-199.456|||||14.368|-62.059|-62.059|0.013|29.5|29.5|3670.836|594887.1667|306.5|40.65|31.19
new_0222_0175|CERE|202112|578.017|565.688||51.7||110.19|42.538|67.652||578.729|-616.244||||-22.3401||||8.2751|||||2.3618|0.729|11.298|0.015|||9|3.9238|||147.3918|200|-0.4|147.7195||147.7195|||-0.4||||-225.334|||||16.649|-59.055|-59.055|0.119|32.42|32.42|4223.3782|430692.7667|95.5368|26.04|26.47
new_0222_0175|CERE|202203|||||||||||||||-22.5852||||8.3552||||||||||||||||||||||||||||||||||||32.67|32.67|4269.704|521536.8333|104.6992||